Twist Bioscience Corporation
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Emily Marine Leproust
- Full Time Employees
- 923
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- 681 Gateway Boulevard South San Francisco CA United States of America 94080
- IPO Date
- Oct 31, 2018
- CIK
- 0001581280
- Website
- twistbioscience.com
- Similar Companies
- Business
- Twist Bioscience Corporation (Nasdaq: TWST), a synthetic biology company founded in 2013 and headquartered in South San Francisco, California, develops and commercializes a proprietary silicon-based platform for high-throughput DNA synthesis that industrializes the engineering of biology; the company manufactures and sells synthetic DNA-based products including synthetic genes and gene fragments for academic research, drug discovery, industrial chemicals, and synthetic biology applications; oligonucleotide pools for CRISPR screening, antibody discovery, and mutagenesis studies; next-generation sequencing (NGS) target enrichment solutions such as customizable panels for clinical diagnostics, cancer research, human genetics, and agrigenomics; biopharma solutions encompassing antibody discovery libraries, optimization services, and integrated discovery platforms; and exploratory DNA data storage solutions offering ultra-high density archival capabilities. Twist operates highly automated manufacturing facilities in South San Francisco, California, and Wilson, North Carolina, serving approximately 2,200 customers across healthcare, agriculture, industrial chemicals, and academic research sectors with global reach in the Americas, EMEA, and Asia-Pacific; the company generates revenue through its e-commerce platform with products priced via volume discounts and custom projects, achieving fiscal 2024 revenue of approximately $289.9 million driven by synthetic biology (genes and oligo pools representing about 60%), NGS tools (about 35%), and emerging biopharma and data storage segments. Recent developments include the October 2024 royalty purchase agreement with XOMA Royalty Corporation providing $15 million in upfront cash in exchange for half of future milestone and royalty payments from existing antibody discovery collaborations while retaining all service revenue and rights to new biopharma deals; expansion of the Express Genes rapid synthesis service launched in November 2023 to midiprep (10-100 micrograms) and maxiprep (100 micrograms-1 milligram) scales in early 2024 to accelerate large-scale experimentation; and collaborations such as the launch of Trinity Freestyle Fast Hybridization Workflow for Element Biosciences' AVITI sequencing system in late 2025 alongside ongoing NGS ProLab partnerships and channel distributor networks to enhance product accessibility and market penetration in high-growth healthcare and biopharma end markets representing nearly 60% of revenue.
Twist Bioscience Director Sold 12,000 Shares. Here's What That Means for Investors.
Twist Bioscience (TWST) Surges 9.3%: Is This an Indication of Further Gains?
Twist Bioscience's Chief Legal Officer Sold Over 14,000 Company Shares. What Does That Mean for Investors?
Healthcare ETFs: PJP Focuses on Pharmaceuticals, While XBI Zeroes in on Biotech
Twist Biosciences' (TWST) CEO Sold 16,000 Shares for $1.1 Million
3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2026
Twist Bioscience to Present at William Blair 46th Annual Growth Stock Conference
Twist Bioscience Corporation (TWST) Analyst/Investor Day Transcript
LenioBio and Twist Bioscience Enter into a Collaboration to Further Enable AI drug-discovery
Twist Bioscience: AI Momentum Is Real, But The Easy Money Has Been Made
These Analysts Boost Their Forecasts On Twist Bioscience After Q2 Results
Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Twist Bioscience Corporation (TWST) Q2 2026 Earnings Call Transcript
AI-Driven Demand Boosts Twist Bioscience Sales, But Loss Widens
Twist Bioscience (TWST) Reports Q2 Loss, Beats Revenue Estimates
Twist Bioscience Expands Clonal Genes Offering to Include Long and Complex Sequences
Twist Bioscience Announces Fiscal 2026 Second Quarter Financial Results
Twist Bioscience to Report Fiscal 2026 Second Quarter Financial Results on Monday, May 4, 2026
Adam Laponis Sells 2,597 Shares of Twist Bioscience (NASDAQ:TWST) Stock
Twist Bioscience (NASDAQ:TWST) Director Sells $51,000.00 in Stock